Contact
searchSearch
HMP Global
Login

Endometrial Cancer

Endometrial Cancer
Specialty Channel
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology
News
Mocertatug Rezetecan Demonstrates Encouraging Activity in Platinum-Resistant Ovarian and Endometrial Cancer
06/17/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1...
06/17/2026
Oncology
News
Mocertatug Rezetecan Shows Promising Efficacy, Manageable Safety in Ovarian and Endometrial Cancer
04/21/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 study demonstrate that mocertatug rezetecan shows clinical promise among patients with platinum-resistant ovarian cancer and recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 study demonstrate that mocertatug rezetecan shows clinical promise among patients with platinum-resistant ovarian cancer and recurrent endometrial cancer.
Results from the phase 1...
04/21/2026
Oncology
News
Pembrolizumab Plus Lenvatinib Shows Promise in Recurrent Gynecologic Clear Cell Carcinomas
02/24/2026
Stephanie Holland
Results from the phase 2 LARA trial demonstrate promising antitumor activity and manageable safety with pembrolizumab plus lenvatinib in patients with recurrent clear cell carcinomas arising from the gynecological tract.
Results from the phase 2 LARA trial demonstrate promising antitumor activity and manageable safety with pembrolizumab plus lenvatinib in patients with recurrent clear cell carcinomas arising from the gynecological tract.
Results from the phase 2 LARA...
02/24/2026
Oncology
Conference Coverage
Metformin Added to Letrozole and Abemaciclib Shows Promise in ER-Positive Endometrial Cancer
06/03/2025
Emily Estrada
The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.
The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.
The addition of metformin to...
06/03/2025
Oncology
Conference Coverage
Durvalumab With or Without Olaparib Plus Chemotherapy for Patients With Mismatch Repair Proficient Endometrial Cancer
03/19/2025
Allison Casey
Exploratory analyses from the DUO-E trial found chemotherapy plus durvalumab with or without olaparib improved the progression-free survival across multiple subgroups of patients with mismatch proficient advanced or recurrent endometrial...
Exploratory analyses from the DUO-E trial found chemotherapy plus durvalumab with or without olaparib improved the progression-free survival across multiple subgroups of patients with mismatch proficient advanced or recurrent endometrial...
Exploratory analyses from the...
03/19/2025
Oncology
Conference Coverage
Addition of Metformin to Letrozole and Abemaciclib Improves Response, PFS Among Patients With Recurrent Estrogen Receptor-Positive Endometrial Cancer
03/17/2025
Allison Casey
According to results from a phase 2 trial, the addition of metformin to letrozole and abemaciclib improved the response and progression-free survival for estrogen receptor-positive recurrent endometrial cancer.
According to results from a phase 2 trial, the addition of metformin to letrozole and abemaciclib improved the response and progression-free survival for estrogen receptor-positive recurrent endometrial cancer.
According to results from a...
03/17/2025
Oncology
Conference Coverage
Endometrial Sampling Among Patients Who Underwent Transvaginal Ultrasound for Postmenopausal Bleeding
03/17/2025
Allison Casey
A large multicenter study found that two-thirds of patients did not receive a timely endometrial sampling as indicated by a thick endometrium or inadequate viewing upon transvaginal ultrasound for postmenopausal bleeding.
A large multicenter study found that two-thirds of patients did not receive a timely endometrial sampling as indicated by a thick endometrium or inadequate viewing upon transvaginal ultrasound for postmenopausal bleeding.
A large multicenter study found...
03/17/2025
Oncology
Quiz
Lenvatinib Plus Pembrolizumab for Patients With Advanced or Recurrent Endometrial Cancer
12/20/2024
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line...
12/20/2024
Oncology

News

News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology
News
Mocertatug Rezetecan Demonstrates Encouraging Activity in Platinum-Resistant Ovarian and Endometrial Cancer
06/17/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1...
06/17/2026
Oncology
News
Mocertatug Rezetecan Shows Promising Efficacy, Manageable Safety in Ovarian and Endometrial Cancer
04/21/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 study demonstrate that mocertatug rezetecan shows clinical promise among patients with platinum-resistant ovarian cancer and recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 study demonstrate that mocertatug rezetecan shows clinical promise among patients with platinum-resistant ovarian cancer and recurrent endometrial cancer.
Results from the phase 1...
04/21/2026
Oncology
News
Pembrolizumab Plus Lenvatinib Shows Promise in Recurrent Gynecologic Clear Cell Carcinomas
02/24/2026
Stephanie Holland
Results from the phase 2 LARA trial demonstrate promising antitumor activity and manageable safety with pembrolizumab plus lenvatinib in patients with recurrent clear cell carcinomas arising from the gynecological tract.
Results from the phase 2 LARA trial demonstrate promising antitumor activity and manageable safety with pembrolizumab plus lenvatinib in patients with recurrent clear cell carcinomas arising from the gynecological tract.
Results from the phase 2 LARA...
02/24/2026
Oncology
Conference Coverage
Metformin Added to Letrozole and Abemaciclib Shows Promise in ER-Positive Endometrial Cancer
06/03/2025
Emily Estrada
The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.
The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.
The addition of metformin to...
06/03/2025
Oncology
Conference Coverage
Durvalumab With or Without Olaparib Plus Chemotherapy for Patients With Mismatch Repair Proficient Endometrial Cancer
03/19/2025
Allison Casey
Exploratory analyses from the DUO-E trial found chemotherapy plus durvalumab with or without olaparib improved the progression-free survival across multiple subgroups of patients with mismatch proficient advanced or recurrent endometrial...
Exploratory analyses from the DUO-E trial found chemotherapy plus durvalumab with or without olaparib improved the progression-free survival across multiple subgroups of patients with mismatch proficient advanced or recurrent endometrial...
Exploratory analyses from the...
03/19/2025
Oncology
Conference Coverage
Addition of Metformin to Letrozole and Abemaciclib Improves Response, PFS Among Patients With Recurrent Estrogen Receptor-Positive Endometrial Cancer
03/17/2025
Allison Casey
According to results from a phase 2 trial, the addition of metformin to letrozole and abemaciclib improved the response and progression-free survival for estrogen receptor-positive recurrent endometrial cancer.
According to results from a phase 2 trial, the addition of metformin to letrozole and abemaciclib improved the response and progression-free survival for estrogen receptor-positive recurrent endometrial cancer.
According to results from a...
03/17/2025
Oncology
Conference Coverage
Endometrial Sampling Among Patients Who Underwent Transvaginal Ultrasound for Postmenopausal Bleeding
03/17/2025
Allison Casey
A large multicenter study found that two-thirds of patients did not receive a timely endometrial sampling as indicated by a thick endometrium or inadequate viewing upon transvaginal ultrasound for postmenopausal bleeding.
A large multicenter study found that two-thirds of patients did not receive a timely endometrial sampling as indicated by a thick endometrium or inadequate viewing upon transvaginal ultrasound for postmenopausal bleeding.
A large multicenter study found...
03/17/2025
Oncology

Interactive Features

Quiz
Lenvatinib Plus Pembrolizumab for Patients With Advanced or Recurrent Endometrial Cancer
12/20/2024
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line...
12/20/2024
Oncology
Quiz
Adjuvant Chemotherapy Plus Radiation for Patients With High-Risk Endometrial Cancer
11/26/2024
Do you know what the 5-year progression-free survival rate among patients with high-risk endometrial cancer was when treated with adjuvant chemotherapy with docetaxel and cisplatin followed by pelvic radiation therapy?
Do you know what the 5-year progression-free survival rate among patients with high-risk endometrial cancer was when treated with adjuvant chemotherapy with docetaxel and cisplatin followed by pelvic radiation therapy?
Do you know what the 5-year...
11/26/2024
Oncology
Quiz
Intraoperative Radiation Therapy for Patients With Recurrent Cervical or Endometrial Cancer
11/26/2024
Is intraoperative radiation therapy a feasible and safe option for certain patients with recurrent or persistent cervical or endometrial cancer?
Is intraoperative radiation therapy a feasible and safe option for certain patients with recurrent or persistent cervical or endometrial cancer?
Is intraoperative radiation...
11/26/2024
Oncology
Quiz
Adjuvant Pembrolizumab Plus Chemotherapy for Patients With Newly Diagnosed, High-Risk Endometrial Cancer
11/12/2024
Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...
Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...
Based on results from the phase...
11/12/2024
Oncology
Quiz
Using the PREMM5 Model to Detect Mutations Associated With Lynch Syndrome
11/06/2024
Is the PREdiction Model for gene Mutations model able to accurately identify patients with endometrial cancer at risk of carrying mutations associated with Lynch Syndrome.
Is the PREdiction Model for gene Mutations model able to accurately identify patients with endometrial cancer at risk of carrying mutations associated with Lynch Syndrome.
Is the PREdiction Model for gene...
11/06/2024
Oncology
Quiz
Response to Datopotamab Deruxtecan Among Patients With Endometrial Cancer
09/30/2024
In the TROPION-PanTumor03 study, what was the confirmed objective response rate among patients with endometrial cancer treated with datopotamab deruxtecan?
In the TROPION-PanTumor03 study, what was the confirmed objective response rate among patients with endometrial cancer treated with datopotamab deruxtecan?
In the TROPION-PanTumor03 study,...
09/30/2024
Oncology
Quiz
Correlation Between Lymph Node Dissection at Hysterectomy and Survival in Patients With Endometrial Cancer
09/30/2024
According to results from a univariable and multivariable analysis, does lymph node dissection at the time of hysterectomy improve overall survival among patients with stage 3 endometrial cancer?
According to results from a univariable and multivariable analysis, does lymph node dissection at the time of hysterectomy improve overall survival among patients with stage 3 endometrial cancer?
According to results from a...
09/30/2024
Oncology
Quiz
Well-Being and Quality of Life in Endometrial Cancer
08/28/2024
Do you know which factors can have the greatest impact on psychological well-being and overall quality of life among patients who have undergone surgery for endometrial cancer? Find out with our quiz.
Do you know which factors can have the greatest impact on psychological well-being and overall quality of life among patients who have undergone surgery for endometrial cancer? Find out with our quiz.
Do you know which factors can...
08/28/2024
Oncology
Quiz
Sacituzumab Govitecan for Patients With Heavily Pretreated Advanced or Metastatic Endometrial Cancer
08/28/2024
Do you know whether sacituzumab govitecan showed promising efficacy among patients with heavily pretreated advanced or metastatic endometrial cancer? Test your knowledge with our quiz.
Do you know whether sacituzumab govitecan showed promising efficacy among patients with heavily pretreated advanced or metastatic endometrial cancer? Test your knowledge with our quiz.
Do you know whether sacituzumab...
08/28/2024
Oncology
Quiz
Maintenance Selinexor for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer
08/08/2024
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance...
08/08/2024
Oncology

Recent News

News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology
News
Mocertatug Rezetecan Demonstrates Encouraging Activity in Platinum-Resistant Ovarian and Endometrial Cancer
06/17/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1...
06/17/2026
Oncology
News
Mocertatug Rezetecan Shows Promising Efficacy, Manageable Safety in Ovarian and Endometrial Cancer
04/21/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 study demonstrate that mocertatug rezetecan shows clinical promise among patients with platinum-resistant ovarian cancer and recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 study demonstrate that mocertatug rezetecan shows clinical promise among patients with platinum-resistant ovarian cancer and recurrent endometrial cancer.
Results from the phase 1...
04/21/2026
Oncology
News
Pembrolizumab Plus Lenvatinib Shows Promise in Recurrent Gynecologic Clear Cell Carcinomas
02/24/2026
Stephanie Holland
Results from the phase 2 LARA trial demonstrate promising antitumor activity and manageable safety with pembrolizumab plus lenvatinib in patients with recurrent clear cell carcinomas arising from the gynecological tract.
Results from the phase 2 LARA trial demonstrate promising antitumor activity and manageable safety with pembrolizumab plus lenvatinib in patients with recurrent clear cell carcinomas arising from the gynecological tract.
Results from the phase 2 LARA...
02/24/2026
Oncology
Conference Coverage
Metformin Added to Letrozole and Abemaciclib Shows Promise in ER-Positive Endometrial Cancer
06/03/2025
Emily Estrada
The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.
The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.
The addition of metformin to...
06/03/2025
Oncology
News
Pembrolizumab Plus Lenvatinib Did Not Significantly Improve Survival for Patients With Mismatch Repair-Proficient Advanced or Recurrent Endometrial Cancer
12/18/2024
Stephanie Holland
Final results from the phase 3 LEAP-001 study demonstrated that first-line lenvatinib plus pembrolizumab did not significantly improve survival compared to lenvatinib plus chemotherapy among patients with pMMR advanced or recurrent...
Final results from the phase 3 LEAP-001 study demonstrated that first-line lenvatinib plus pembrolizumab did not significantly improve survival compared to lenvatinib plus chemotherapy among patients with pMMR advanced or recurrent...
Final results from the phase 3...
12/18/2024
Oncology
News
Chronic Stress May Contribute to Progression of Metastatic Endometrial Cancer
12/05/2024
Allison Casey
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated...
12/05/2024
Oncology
News
Dostarlimab Plus Chemotherapy Reduces the Risk of Progression or Death for Patients With dMMR/MSI-H Advanced or Recurrent Endometrial Cancer
11/26/2024
Stephanie Holland
According to additional results from the RUBY trial, dostarlimab plus chemotherapy reduced the risk of progression or death among patients with mismatch repair deficient or microsatellite instability-high advanced or recurrent endometrial...
According to additional results from the RUBY trial, dostarlimab plus chemotherapy reduced the risk of progression or death among patients with mismatch repair deficient or microsatellite instability-high advanced or recurrent endometrial...
According to additional results...
11/26/2024
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use